Holen Sie sich die Stockscreener-App
0.47
8.88%
-0.048
Schlusskurs vom Vortag:
$0.518
Offen:
$0.52
24-Stunden-Volumen:
119.20K
Relative Volume:
0.49
Marktkapitalisierung:
$19.79M
Einnahmen:
$14.92M
Nettoeinkommen (Verlust:
$-86.88M
KGV:
-0.137
EPS:
-3.43
Netto-Cashflow:
$-82.31M
1W Leistung:
+7.73%
1M Leistung:
-39.38%
6M Leistung:
-58.04%
1J Leistung:
-83.01%
1-Tages-Spanne:
$0.4678
$0.52
1-Wochen-Bereich:
$0.44
$0.6179
52-Wochen-Spanne:
$0.38
$2.94
Carisma Therapeutics Inc Stock (CARM) Company Profile
Firmenname
Carisma Therapeutics Inc
Sektor
Branche
Telefon
(267) 491-6422
Adresse
3675 MARKET STREET, PHILADELPHIA
Vergleichen Sie CARM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.4741 | 19.79M | 14.92M | -86.88M | -82.31M | -3.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-04-11 | Eingeleitet | BTIG Research | Buy |
| 2023-10-03 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-06 | Eingeleitet | Evercore ISI | Outperform |
| 2023-05-31 | Hochstufung | Jefferies | Hold → Buy |
| 2023-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Carisma Therapeutics Inc Aktie (CARM) Neueste Nachrichten
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World
Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow
Carisma Therapeutics Appoints Interim VP of Finance - TipRanks
Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN
Carisma downgraded by H.C. Wainwright to neutral - MSN
Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN
Carisma Therapeutics (NASDAQ:CARM) Cut to Neutral at Robert W. Baird - Defense World
Carisma downgraded by Baird over lack of near-term catalysts - MSN
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Kilgore News Herald
Baird Downgrades Carisma Therapeutics (CARM) - MSN
BTIG cuts Carisma Therapeutics to Neutral from Buy By Investing.com - Investing.com Nigeria
Carisma downgraded by Baird over lack of near-term catalysts (CARM:NASDAQ) - Seeking Alpha
Carisma Therapeutics downgraded to Neutral from Outperform at Baird - MSN
BTIG Downgrades Carisma Therapeutics (CARM) - MSN
Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 - The Eastern Progress Online
Carisma Therapeutics cut to In Line, stock target slashed on tempered outlook - Investing.com
Carisma Therapeutics Drops GC As Part Of Cutbacks - Law360
Carisma Therapeutics Announces Strategic Restructuring to Re-Prioritize Pipeline and A Reduction in the Workforce by 34% - Marketscreener.com
Carisma Therapeutics shifts focus, cuts workforce by 34% - Investing.com Nigeria
BTIG cuts Carisma Therapeutics to Neutral from Buy - Investing.com
Penn spinout Carisma Therapeutics to narrow R&D focus, lay off more than a third of its workforce - The Business Journals
Carisma Therapeutics shifts focus, cuts workforce by 34% By Investing.com - Investing.com South Africa
Carisma Therapeutics Reprioritizes Pipeline, Cuts Jobs - Contract Pharma
Carisma Therapeutics Announces Strategic Restructuring to Re-pri - GuruFocus.com
Carisma Therapeutics Restructures Amid Strategic Refocus - TipRanks
Carisma Therapeutics Pivots Strategy, Cuts 34% of Workforce to Focus on Macrophage Platform - StockTitan
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma - The Eastern Progress Online
Carisma Therapeutics to Present at Upcoming Conferences - The Eastern Progress Online
Carisma Therapeutics Announces Changes to its Board of Directors - The Eastern Progress Online
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28% - Simply Wall St
CARM Stock Hits 52-Week Low at $0.8 Amid Market Challenges - Investing.com
Carisma Therapeutics CEO to Speak at 7th Annual Evercore ISI HealthCONx Conference - MSN
Carisma Therapeutics Announces Upcoming Presentations at SITC 20 - GuruFocus.com
Carisma Therapeutics stock target cut, maintains buy on clinical trial - Investing.com
Carisma Therapeutics stock target cut, maintains buy on clinical trial By Investing.com - Investing.com Canada
Carisma Therapeutics price target lowered to $5 from $8 at H.C. Wainwright - TipRanks
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CA - GuruFocus.com
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs - MSN
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MSN
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PR Newswire
Finanzdaten der Carisma Therapeutics Inc-Aktie (CARM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):